Antithrombotic and thrombolytic therapy for ischemic stroke.

Area of Science:

• Neurology
• Pharmacology
• Cardiovascular Medicine

Background:

• Thrombolytic and antithrombotic agents are crucial for stroke management.
• Recombinant tissue plasminogen activator (rt-PA) improves outcomes when administered within 3 hours of stroke onset.
• Research is ongoing to extend the therapeutic window for rt-PA and develop safer alternatives.

Purpose of the Study:

• To review the current landscape of thrombolytic and antithrombotic therapies for stroke.
• To highlight the role of antiplatelet agents in preventing atherothrombotic stroke recurrence.
• To discuss the prevention of cardioembolic stroke using oral anticoagulation.

Main Methods:

• Review of existing literature on thrombolytic and antithrombotic agents.
• Analysis of data from large, randomized trials on antiplatelet therapy.
• Examination of guidelines and evidence for oral anticoagulation in stroke prevention.

Main Results:

• Recombinant tissue plasminogen activator demonstrates efficacy in acute ischemic stroke within a limited time window.
• Early and continuous antiplatelet therapy, including agents more effective than aspirin, reduces atherothrombotic stroke recurrence.
• Oral anticoagulation is the primary strategy for preventing cardioembolic stroke.

Conclusions:

• Optimizing thrombolytic therapy and exploring new agents are key research areas.
• Advanced antiplatelet agents offer improved efficacy over aspirin for secondary stroke prevention.
• Appropriate anticoagulation remains essential for managing cardioembolic stroke risk.